The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|13|2089-2099

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.13, 2014-04, pp. : 2089-2099

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Involvement of the Endocannabinoid System in Motor Disorders

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Iss. 3, 2004-09 ,pp. : 175-182

Bentham Science Publishers

Access to resources Recommend Favorite

The Endocannabinoid System and Schizophrenia: Integration of Evidence

By  

Current Pharmaceutical Design, Vol. 18, Iss. 32, 2012-11 ,pp. : 4980-4990

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the endocannabinoid system in treating brain disorders

By Bahr Ben A   Karanian David A   Makanji Sagar S   Makriyannis Alexandros  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 351-365

Informa Healthcare

Access to resources Recommend Favorite

The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 451-458

Bentham Science Publishers

Access to resources Recommend Favorite

Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor

By Garcia de Mateos-Verchere J.   Vaugeois J.-M.   Naudin B.   Costentin J.  

European Neuropsychopharmacology, Vol. 8, Iss. 4, 1998-12 ,pp. : 255-259

Elsevier

Access to resources Recommend Favorite